ALK and non-small cell lung carcinoma: The rearrangements of anaplastic lymphoma kinase (ALK) gene occur in approximately 3-5% of NSCLC patients and ALK-positive NSCLC patients are highly sensitive to ALK receptor tyrosine kinase inhibitors (TKIs) (2, 13, 14).